RxDoctor Payments Data

Richard Yee, DO

Family Medicine · Lodi, CANPI 1225095235

Payments from drug & device makers

$2,475in general payments, 2019–2025

Across 161 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$502
  • Pfizer$283
  • Boehringer Ingelheim$281
  • Johnson & Johnson$265
  • Merck$222
  • Kowa Pharmaceuticals America, Inc.$128
  • plus $795 from 17 others

What the payments were for

  • Food & beverage$2,44699%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,475 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$277,697
Medicare patients
555
Services billed
2,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$100,164
JardianceEmpagliflozin72$53,695
JanuviaSitagliptin Phosphate25$37,342
TrulicityDulaglutide28$31,627
OzempicSemaglutide30$27,050
XareltoRivaroxaban19$20,430
RybelsusSemaglutide13$16,549
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,038
Breo ElliptaFluticasone/Vilanterol27$10,685
Atorvastatin Calcium711$6,437
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen201$5,990
Levemir FlexpenInsulin Detemir15$4,973
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$4,914
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$4,035
SynthroidLevothyroxine Sodium55$3,978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$283$100,164112 claims
Boehringer IngelheimJardiance$281$53,69572 claims
Novo NordiskOzempic, Rybelsus$123$43,59943 claims
MerckJanuvia$222$37,34225 claims
Lilly USA, LLCTrulicity$116$31,62728 claims
Johnson & JohnsonXarelto$265$20,43019 claims
AstraZenecaBevespi Aerosphere$502$4,03511 claims
AbbVieSynthroid$34$3,97855 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Lodi

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →